Article and Study Summary: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Published in: N Engl J Med. 2022;387(9):810-823 https://www.nejm.org/doi/full/10.1056/NEJMoa2119430 Authors: Conradie F, Bagdasaryan TR, Borisov S, et al. Summary: The...
Abstract: In 2021, long-acting cabotegravir (LA CAB) was approved by the United States Food and Drug Administration for an indication of pre-exposure prophylaxis in women. This is a first in what is hoped to be a robust pipeline of long-acting antiretroviral agents...
Article and Study Summary: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial Published in: Lancet HIV. 2022;9(7):e464-e473 https://doi.org/10.1016/S2352-3018(22)00126-6 Authors: Ngure...
Article and Study Summary: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial Published in: Lancet. 2022;399(10337):1779-1789 https://doi.org/10.1016/S0140-6736(22)00538-4 Authors: Delany-Moretlwe S, Hughes...
The novel coronavirus disease COVID-19 caused by SARS-CoV-2 threatens to disrupt global progress toward HIV epidemic control. Opportunities exist to leverage ongoing public health responses to mitigate the impacts of COVID-19 on HIV services, and novel approaches to...
